Filing Flows › International Stem Cell (ISCO) › Q1 2026
International Stem Cell (ISCO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
International Stem Cell (ISCO) reported revenue of $2.3M for the first quarter 2026 (Q1 2026), +9% from a year earlier and +7% from the quarter before. Operating margin was -8.2%, net loss $220K (9.5% of revenue).
International Stem Cell, Q1 2026: revenue $2.3M (+9% year over year), operating margin -8.2%, net loss $220K, operating cash flow $121K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.3M | +7% | +9% |
| Operating profit | −$190K | — | — |
| Net earnings | −$220K | — | — |
| Operating cash flow | $121K | +278% | -47% |
| Free cash flow | $98K | +238% | -56% |
What changed
Revenue was $2.3M in Q1 2026, up 9% year over year and up 7% from the previous quarter. Biomedical Market was the largest line at 94% of revenue. Biomedical Market added $175K year over year (up 9%), 94% of the total change.
Operating costs exceeded revenue by $190K, an operating margin of -8.2%. Total costs grew 7% against revenue growth of 9%. The fastest-growing cost line was General & admin (+26%). The quarter ended with a net loss of $220K, narrower than the previous quarter's $348K loss.
Operating cash flow was $121K (down 47% year over year). Non-cash charges added back $34K of depreciation and amortization and $64K of share-based compensation. Working capital and other items added $243K. Capital expenditures of $23K left free cash flow of $98K.
Questions
What was International Stem Cell's revenue in the first quarter 2026?
International Stem Cell (ISCO) reported revenue of $2.3M for the first quarter 2026 (Q1 2026), +9% from a year earlier and +7% from the quarter before.
Was International Stem Cell profitable in the first quarter 2026?
Operating loss was $190K (-8.2% of revenue) and net loss $220K.